Back to top
more

Anika Therapeutics (ANIK)

(Real Time Quote from BATS)

$25.83 USD

25.83
5,536

+0.40 (1.57%)

Updated Apr 19, 2024 10:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ANIK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Anika Therapeutics Inc. [ANIK]

Reports for Purchase

Showing records 1 - 16 ( 16 total )

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for ANIK 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

08/30/2022

Industry Report

Pages: 14

Hyaluronic Acid Overview and Reimbursement Changes

Provider: KEYBANC CAPITAL MARKETS

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ANIK

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/10/2020

Company Report

Pages: 4

Dropping Coverage

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/04/2020

Company Report

Pages: 4

New Pricing Data Raises Risks

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/24/2020

Company Report

Pages: 4

Underlying Business Shrinking

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

02/24/2020

Company Report

Pages: 4

Underlying Business Shrinking

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

01/10/2020

Company Report

Pages: 4

Detached Joints

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/10/2019

Company Report

Pages: 4

Dissolving Revenue

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/05/2019

Company Report

Pages: 4

Revenue-itis, Initiating w/Sell

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/04/2019

Industry Report

Pages: 1

INDUSTRY UPDATE

Provider: SINGULAR RESEARCH

Analyst: MALTBIE R

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

02/28/2019

Company Report

Pages: 8

We maintain a Buy-Long-term rating, but reduce our price target from $55 to $45.

Provider: SINGULAR RESEARCH

Analyst: SPRINGER L

Price: 25.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/21/2015

Industry Report

Pages: 2

Boost for Medical/ Dental/ Veterinary Companies-Protecting Americans from Tax Hikes Act of 2015 (PATH) - Highlights

Provider: G.RESEARCH, LLC

Analyst: TSAI J

Price: 10.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/08/2015

Industry Report

Pages: 19

Comparative Oncology: A New Breed of Trial Set to Improve Clinical Success in Oncology

Provider: DAWSON JAMES SECURITIES, INC.

Price: 50.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/18/2011

Daily Note

Pages: 6

A FOUR STAR A PATENTVEST IP GROWTH COMPANY - 2011 BEST AND BRIGHTEST PATENTVEST REPORTS

Provider: MDB CAPITAL GROUP LLC

Price: 25.00

Research Provided by a Third Party

Company: Anika Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

07/21/2010

Industry Report

Pages: 68

THE REGENERATIVE MEDICINE REPORT: Part I - Investment Analysis of the Regenerative Medicine Industry - Highlighting Emerging Technologies and Valuable Intellectual Property

Provider: MDB CAPITAL GROUP LLC

Analyst: HOBBIB G

Price: 150.00

Research Provided by a Third Party